Inhibitex has acquired 1 company of its own.
Inhibitex has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).
9005 Westside Parkway,
Alpharetta, Georgia
30009
United States,
(678)746-1100
www.inhibitex.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2007-04-10 |
FermaVir Pharmaceuticals, Inc. · Life Science
New York, New York · www.fermavir.com FermaVir Pharmaceuticals, Inc. is a biotechnology company that develops antiviral drugs and other treatments in underserved segments of the pharmaceutical development marketplace. FermaVir’s Intellectual Property portfolio includes a number of patent applications and a worldwide exclusive license for potential new drug treatments of infectious diseases. Among FermaVir's lead drug candidates is FV-100, a potential breakthrough antiviral treatment that has demonstrated powerful inhibitory activity and may have potential therapeutic benefit for the treatment of shingles, also known as herpes zoster. |
- | Add-on Acquisition | - |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
